IP Library Granted Patent US 8,562,947
Granted Patent B2
US 8,562,947 · App. 12/670,925 · Granted Oct 22, 2013

Oxidized avidin with high residency time in the treated tissues

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,562,947
App. No.
12/670,925
Granted
Oct 22, 2013
Kind
B2
Abstract

The present invention describes chemically modified avidins that have higher permanence in treated tissues compared to wild type avidin. Avidin oxidation is performed by periodate incubation in the presence of the low affinity ligand HABA which, occupying the biotin binding sites, prevents protein denaturation during the oxidation step. Periodate oxidation generates CHO groups from avidin mannose ring opening that, once injected, react with tissue NH 2 residues to form stable Schiff's bases. The anchored avidins maintain the ability to bind biotinylated agents endowed of therapeutic activity, like radiolabeled biotins, stem cells and somatic cells, useful for brachytherapies like Intraoperative Avidination Radionuclide Therapy (IART®) or degenerative or genetic diseases.

Claims (8)

1. An oxidized avidin in which at least one mannose residue per avidin molecule is replaced by a residue of the following formula

wherein said oxidized avidin contains about 8 to 15 aldehyde moieties and has a thermal stability equal to or greater than 78° C.

2. A complex consisting of the oxidized avidin according to claim 1 and a biotinylated therapeutic agent.

3. The complex according to claim 2 , wherein the biotinylated therapeutic agent is an anticancer agent.

4. A pharmaceutical composition comprising an oxidized avidin in which at least one mannose residue per avidin molecule is replaced by a residue of the following formula

wherein said oxidized avidin contains about 8 to 15 aldehyde moieties and has a thermal stability equal to or greater than 78° C. or the complex according to claim 2 with a pharmaceutically acceptable excipient thereof.

5. A kit comprising the pharmaceutical composition according to claim 4 containing the oxidized avidin in a first container and the biotinylated therapeutic agent in a second container.

6. The kit according to claim 5 for a two-step adjuvant intra- and perioperative locoregional and/or systemic therapy, wherein the two containers have the form of a syringe.

Assignments (3)
CHANGE OF ADDRESS Recorded Oct 15, 2019
From: ALFASIGMA S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 050727/0652 →
MERGER Recorded Nov 14, 2017
From: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
To: ALFASIGMA S.P.A.
Reel/Frame 044760/0906 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2010
From: DE SANTIS, RITA; NUZZOLO, CARLO ANTONIO
To: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A
Reel/Frame 023980/0737 →